Meeting
2023 ASCO Annual Meeting
Use of proteomimetic polymers for delivery of tumor antigens and adjuvants through formation of stable electrostatic complexes with small molecule STING agonists.
Authors
Max Mu Wang
Medical Scientist Training Program, Northwestern University, Chicago, IL
Max Mu Wang , Brayley Gattis , Mi Ran Choi , Bin Zhang , Nathan Gianneschi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2583)
DOI
10.1200/JCO.2023.41.16_suppl.2583
Abstract #
2583
Poster Bd #
425
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
First Author: Sofie Kirial Mørk
Poster
2022 ASCO Annual Meeting
A novel polymeric peptide delivery platform and association with targeted co-delivery of antigens and STING agonists with antitumor immune response.
First Author: Max Mu Wang
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I/IIa clinical trial investigating the therapeutic cancer vaccine UV1 in combination with ipilimumab in patients with malignant melanoma: Four-year survival update.
First Author: Espen Basmo Ellingsen
Poster
2018 ASCO Annual Meeting
Pilot trial of an indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor plus a multipeptide melanoma vaccine in patients with advanced melanoma.
First Author: Craig L. Slingluff Jr.